Serious infections associated with anticytokine therapies in the rheumatic diseases (Q35937819)

11 August 2017

1 reference

title

Serious infections associated with anticytokine therapies in the rheumatic diseases (English)

1 reference

11 August 2017

Jon T Giles

1

1 reference

PubMed ID

15523118

11 August 2017

Joan M Bathon

series ordinal

2

1 reference

11 August 2017

1 November 2004

1 reference

Journal of Intensive Care Medicine

11 August 2017

1 reference

11 August 2017

19

1 reference

11 August 2017

320-334

1 reference

11 August 2017

6

1 reference

Cytokine pathways and joint inflammation in rheumatoid arthritis

11 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Predictors of infection in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Management of tuberculosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Corticosteroids in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Anti-cytokine therapeutics and infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

The role of cytokines in the immune response to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Immune evasion by Mycobacterium tuberculosis: living with the enemy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Immunology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Disseminated tuberculosis in interferon gamma gene-disrupted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Restraining mycobacteria: role of granulomas in mycobacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Tuberculous tonsillitis in a patient receiving etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Histoplasma capsulatum molecular genetics, pathogenesis, and responsiveness to its environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Immune response to early and late Histoplasma capsulatum infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Listeria monocytogenes: clinical and experimental update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

Anakinra treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066604267854

21 January 2018

Identifiers

DOI

10.1177/0885066604267854

1 reference

11 August 2017

1 reference

PubMed ID

15523118